Helius Medical Q3 revenue $143K, net loss $3.7M; cash runway into Q2 2024

Solana Co

2023-Q3 EPS reported -$13.60 revenue$510,000

Q3 revenue $143K vs $196K YoY; decline due to PTAP expiration on June 30.
Net loss $3.7M vs $1.0M; basic EPS loss $5.49 vs $2.90.
Cash $6.6M plus $0.4M in warrant proceeds; operating burn $2.5M; runway into Q2 2024.
Received UPC codes for PoNS system ($25,700) and mouthpiece ($7,900) from Medi-Span.
Quebec MSSS LOI for up to 30 PoNS systems; UdeM order for 10 systems.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Solana Co reported the quarter ended September 30, 2023 results: revenue $143 thousand, net income Net loss was $3.7 million for the third quarter of 2023.

Period: the quarter ended September 30, 2023
Revenue: $143 thousand
Net income: Net loss was $3.7 million for the third quarter of 2023
Result: reported results

Exact text from the filing

approach for balance and gait deficits, today announced results for the quarter ended September 30, 2023. Third Quarter and Recent Business Updates ● Q3 2023 revenue of $143 thousand, compared to $196 thousand in Q3 2022, the decrease due to the expiration of the Patient Therapy Access Program (“PTAP”) on June 30, 2023. ● Operating cash burn of $2.5 million

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Solana Co filing history →

Source: SEC EDGAR

accession 0001558370-23-018580

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.